-
1.发明授权
公开(公告)号：US5458140A
公开(公告)日：1995-10-17
申请号：US152442
申请日：1993-11-15
CPC分类号： A61B5/1486 , A61B5/14514 , A61B5/681 , A61K41/0047 , A61K49/22 , A61B18/203 , A61B2017/00172 , A61B2017/00765 , A61B2018/00452 , A61B2018/0047 , A61B2562/0295 , A61M2037/0007 , A61M37/0092
摘要： A method of enhancing the permeability of the skin or mucosa to an analyte for diagnostic purposed is described utilizing ultrasound or ultrasound plus a chemical enhancer. If desired the ultrasound may be modulated by means of frequency modulation, amplitude modulation, phase modulation and/or combinations thereof. A frequency modulation from low to high develops a local pressure gradient directed out of the body, thus permitting analytes in the body to traverse the skin and be collected and measured outside the body. The concentration of an analyte in the body is preferably determined by enhancing the permeability of the skin or other biological membrane optionally with a chemical enhancer, applying ultrasound optionally at a modulated frequency, amplitude, phase, or combinations thereof that further induces a local pressure gradient out of the body, collecting the analyte, and utilizing the analyte collection data calculating the concentration of the analyte in the body.
摘要翻译： 使用超声波或超声波加上化学增强剂来描述增强皮肤或粘膜对于诊断用途分析物的渗透性的方法。 如果需要，可以通过频率调制，幅度调制，相位调制和/或其组合来调制超声波。 从低到高的频率调制产生了引导出身体的局部压力梯度，从而允许身体中的分析物穿过皮肤并在体外被收集和测量。 体内分析物的浓度优选通过任选地用化学增强剂增强皮肤或其他生物膜的渗透性，任选地以调制的频率，幅度，相位或其组合施加超声来进一步诱导局部压力梯度来确定 收集分析物，并利用分析物收集数据计算体内分析物的浓度。
-
2.发明授权
公开(公告)号：US5445611A
公开(公告)日：1995-08-29
申请号：US152174
申请日：1993-12-08
CPC分类号： A61B5/14514 , A61M37/0092 , A61B18/203 , A61B2017/00172 , A61B2017/00765 , A61B2018/00452 , A61B2018/0047
摘要： A method of enhancing the permeability of the skin or mucosa to a biologically active permeant or drug is described utilizing ultrasound or ultrasound plus a chemical enhancer. If desired the ultrasound may be modulated by means of frequency modulation, amplitude modulation, phase modulation and/or combinations thereof. A frequency modulation from high to low develops a local pressure gradient directed into the body, thus permitting permeant to traverse the skin or mucosa. The enhanced delivery is preferably accomplished using a chemical enhancer, applying ultrasound optionally at a modulated frequency, amplitude, phase, or combinations thereof that further induces a local pressure gradient into the body. The method is also useful as a means for application of a tattoo by noninvasively delivering a pigment through the skin surface.
摘要翻译： 使用超声波或超声波加上化学增强剂来描述增强皮肤或粘膜对生物活性透过物或药物的渗透性的方法。 如果需要，可以通过频率调制，幅度调制，相位调制和/或其组合来调制超声波。 从高到低的频率调制产生引导到身体中的局部压力梯度，从而允许透过物穿过皮肤或粘膜。 增强的递送优选使用化学增强剂完成，任选地以调制的频率，幅度，相位或其组合施加超声波，其进一步诱导局部压力梯度进入体内。 该方法也可用作通过非侵入性地通过皮肤表面递送颜料来施加纹身的手段。
-
公开(公告)号：US5783179A
公开(公告)日：1998-07-21
申请号：US743613
申请日：1991-08-09
申请人： John J. Nestor, Jr. , Teresa H. Ho , Deborah A. Eppstein , Philip L. Felgner , Barbara P. Barna , Sharad D. Deodhar
发明人： John J. Nestor, Jr. , Teresa H. Ho , Deborah A. Eppstein , Philip L. Felgner , Barbara P. Barna , Sharad D. Deodhar
CPC分类号： C07K14/4737 , A61K38/00
摘要： Compounds having immunomodulatory activity comprising the optionally modified dodecapeptide fragment A-(SEQ ID No: 1)-B corresponding to residues 174 to 185 of C-reactive protein (CRP), pharmaceutical compositions thereof, and methods of treating cancer with the compositions. Liposomal formulations containing the CRP-peptide fragment are particularly efficacious when administered in conjunction with interleukin-2.
摘要翻译： 具有免疫调节活性的化合物包含对应于C-反应蛋白（CRP）的残基174至185的任选修饰的十二肽片段A-（SEQ ID No：1）-B，其药物组合物，以及用该组合物治疗癌症的方法。 含有CRP-肽片段的脂质体制剂与白介素-2联用时特别有效。
-
4.发明授权Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides 失效连续注射胞壁酰二肽和脂质体可增强胞壁酰二肽的抗感染活性
公开(公告)号：US4522811A
公开(公告)日：1985-06-11
申请号：US396213
申请日：1982-07-08
摘要： Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
摘要翻译： 连续注射胞壁酰二肽和脂质体可增强胞壁酰二肽的抗感染活性。
-
5.发明授权N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor 失效N-（1,1-（1,1-） - 二烷氧基） - 和N-（1，（1,1-） - 二烯基氧基烷-1-基-N-N，N-四取代的铵脂质及其用途
公开(公告)号：US5550289A
公开(公告)日：1996-08-27
申请号：US415963
申请日：1995-04-03
IPC分类号： A61K9/127 , A61K47/18 , C07D453/02 , C12N15/88 , C07C213/06 , A61F2/02 , A61K9/70
CPC分类号： A61K47/186 , A61K9/0014 , A61K9/0019 , A61K9/1272 , C07D453/02 , C12N15/88 , Y10S435/829
摘要： This invention relates to compounds of the formula ##STR1## or an optical isomer thereof wherein R.sup.1 and R.sup.2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R.sup.3, R.sup.4 and R.sup.5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R.sup.3, R.sup.4, and R.sup.5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
摘要翻译： 本发明涉及式I的化合物或其旋光异构体，其中R 1和R 2相同或不同，为6至24个碳原子的烷基或烯基; R3，R4和R5相同或不同，为碳原子数为1〜8的烷基，芳基，碳原子数为7〜11的芳烷基，或者当R3，R4，R5中的两个或三个为一体时，可以形成奎宁二基，哌啶子基 ，吡咯烷子基或吗啉代; n为1至8; X是药学上可接受的阴离子。
-
6.发明授权N-.omega.,(.omega.-1)-dialkyloxy)- and N-(.omega.,(.omega.-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor 失效N-ω，（ω-1） - 二烷氧基）和N-（ω，（ω-1） - 二烯氧基）Alk-1-YL-N，N，N-四取代的铵脂质及其用途
公开(公告)号：US5049386A
公开(公告)日：1991-09-17
申请号：US524257
申请日：1990-05-15
IPC分类号： A61K9/127 , A61K47/18 , C07D453/02 , C12N15/88
CPC分类号： C07D453/02 , A61K47/186 , A61K9/0014 , A61K9/0019 , A61K9/1272 , C12N15/88
摘要： This invention relates to compounds of the formula ##STR1## or an optical isomer thereof wherein R.sup.1 and R.sup.2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R.sup.3, R.sup.4 and R.sup.5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R.sup.3, R.sup.4, and R.sup.5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
摘要翻译： 本发明涉及式I的化合物或其旋光异构体，其中R 1和R 2相同或不同，为6至24个碳原子的烷基或烯基; R 3，R 4和R 5相同或不同，为碳原子数为1〜8的烷基，芳基，碳原子数为7〜11的芳烷基，或者当R3，R4，R5中的2个或3个为一起形成亚硝酰基，哌啶子基 ，吡咯烷子基或吗啉代; n为1至8; X是药学上可接受的阴离子。
-
7.发明申请Methods and Compositions for Expanding, Identifying, Characterizing and Enhancing Potency of Mammalian-Derived Glial Restricted Progenitor Cells 审中-公开用于扩增，鉴定，表征和提高哺乳动物衍生的胶质受限祖细胞的效力的方法和组合公开(公告)号：US20120230963A1
公开(公告)日：2012-09-13
申请号：US13508803
申请日：2010-11-09
IPC分类号： C12N5/0797 , C12N5/079 , A61P25/28 , C40B30/04 , A61K35/30 , A61P25/00 , C12N13/00 , C40B40/10
CPC分类号： C12N5/0622
摘要： Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
摘要翻译： 提供了用于产生具有降低的潜在非预期或不需要的细胞表型的人衍生的神经胶质细胞祖细胞（GRP）群体和/或群体细胞中标准偏差降低的方法。 还提供了表征GRP的抗体组和基因表达谱以及用于表征GRP细胞的方法。 另外还提供了使用这些GRP细胞产生星形胶质细胞和/或少突胶质细胞，再髓鞘神经元和治疗胶质细胞相关和其它神经变性疾病或障碍或对神经系统的损伤或损伤的方法。 还提供了制备耗尽A2B5阳性细胞的神经细胞的方法。
-
![N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor](/abs-image/US/2002/05/14/US06387395B1/abs.jpg.150x150.jpg)
8.发明授权N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 失效N- [1，（1-1） - 二烷氧基] - 和N- [1,1-（1,1-） - 二烯氧基] - 烷-1-基-N，N，N-四取代的铵脂质及其用途公开(公告)号：US06387395B1
公开(公告)日：2002-05-14
申请号：US08348635
申请日：1994-12-02
IPC分类号： A61K9127
CPC分类号： C07D453/02 , A61K9/0014 , A61K9/0019 , A61K9/1272 , A61K47/186 , C12N15/88 , Y10S435/829
摘要： This invention relates to compounds of the formula or an optical isomer thereof wherein R1 and R2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R3, R4 and R5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R3, R4, and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
摘要翻译： 本发明涉及式的化合物或其光学异构体，其中R 1和R 2相同或不同，为6至24个碳原子的烷基或烯基; R3，R4和R5相同或不同，为碳原子数为1〜8的烷基，芳基，碳原子数为7〜11的芳烷基，或者当R3，R4，R5中的2个或3个相同时，可以形成奎宁二基，哌啶子基 ，吡咯烷子基或吗啉代; n为1至8; X是药学上可接受的阴离子。
-
公开(公告)号：US4962091A
公开(公告)日：1990-10-09
申请号：US866625
申请日：1986-05-23
IPC分类号： A61K38/00 , A61K9/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/70 , A61K38/21 , A61K38/23 , A61K38/27 , A61K47/00 , A61K47/34
CPC分类号： A61K9/7007 , A61K9/1647 , A61K9/204 , Y10S514/964
摘要： An active agent delivery system for the controlled administration of macromolecular polypeptides which comprises a micro-suspension of water-soluble components in a polylactide matrix.
-
10.发明授权N-(.omega.,(.omega.-1)-dialkyloxy)- and N-(.omega.,(.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 失效N-（ω，（ω-1） - 二烷氧基） - 和N-（ω，（ω-1） - 二烯氧基） - 烷基-1-基-N，N，N-四取代的铵脂质及其用途
公开(公告)号：US4946787A
公开(公告)日：1990-08-07
申请号：US428815
申请日：1989-10-27
IPC分类号： A61K9/127 , A61K47/18 , C07D453/02 , C12N15/88
CPC分类号： C12N15/88 , A61K47/186 , A61K9/0014 , A61K9/0019 , A61K9/1272 , C07D453/02
摘要： This invention relates to compounds of the formula ##STR1## or an optical isomer thereof wherein R.sup.1 and R.sup.2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R.sup.3, R.sup.4 and R.sup.5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R.sup.3, R.sup.4, and R.sup.5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
摘要翻译： 本发明涉及式I的化合物或其旋光异构体，其中R 1和R 2相同或不同，为6至24个碳原子的烷基或烯基; R 3，R 4和R 5相同或不同，为碳原子数为1〜8的烷基，芳基，碳原子数为7〜11的芳烷基，或者当R3，R4，R5中的2个或3个为一起形成亚硝酰基，哌啶子基 ，吡咯烷子基或吗啉代; n为1至8; X是药学上可接受的阴离子。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.03 秒)
